mRNA-COVID19 Vaccination Can Be Considered Safe and Tolerable for Frail Patients

Area of Science:

• Immunology
• Oncology
• Neurology
• Rheumatology

Background:

• Frail patients with malignancies or neurological/rheumatological diseases are at high risk for COVID-19 complications.
• Vaccine hesitancy in this cohort stems from lack of inclusion in initial trials and fear of adverse events.
• The VAX4FRAIL study addresses the safety of COVID-19 vaccination in frail, trans-disease populations.

Purpose of the Study:

• To evaluate the safety profile of mRNA COVID-19 vaccines in frail patients.
• To assess vaccine adverse events in patients with hematological malignancies, solid tumors, and neurological or rheumatological diseases.

Main Methods:

• Prospective, multicenter study (VAX4FRAIL) involving 566 frail patients.
• Administration of mRNA-1273 or BNT162b2 vaccines.
• Assessment of health status via questionnaire focusing on the week post-vaccination.

Main Results:

• Common moderate-severe adverse events included injection site pain, fatigue, bone pain, and headache.
• Age, female sex, and mRNA-1273 vaccine were associated with increased risk of severe symptoms.
• A small percentage of patients required treatment postponement; two unrelated fatal events occurred.

Conclusions:

• mRNA COVID-19 vaccination is safe in frail patients across various disease categories.
• Reported side effects are manageable and have minimal impact on patient care pathways.
• The study provides crucial safety data for vaccinating vulnerable patient groups.